Lineage Cell Therapeutics, Inc. (LCTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $535.72M; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.47M; Retained Earnings (Accumulated Deficit)USD $-470.33M.
- 2026-03-31: Common Stock, Value, IssuedUSD $529.66M; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.97M; Retained Earnings (Accumulated Deficit)USD $-471.81M.
- 2025-12-31: Common Stock, Value, IssuedUSD $515.47M; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD $3.90M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.92M; Retained Earnings (Accumulated Deficit)USD $-467.00M.
- 2025-09-30: Common Stock, Value, IssuedUSD $494.18M; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.29M; Retained Earnings (Accumulated Deficit)USD $-467.85M.
Lineage Cell Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Noncontrolling Interest, Increase from Business Combination USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $535.72M | (m) | $-4.47M | $-470.33M | $60.92M | $59.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $529.66M | (m) | $-3.97M | $-471.81M | $53.88M | $52.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $515.47M | $3.90M | $-3.92M | $-467.00M | $44.55M | $43.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $494.18M | (m) | $-4.29M | $-467.85M | $22.04M | $20.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $490.55M | (m) | $-4.10M | $-438.07M | $48.38M | $47.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $489.31M | (m) | $-2.68M | $-407.60M | $79.03M | $77.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $484.72M | $2.90M | $-2.88M | $-403.46M | $78.38M | $77.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $469.27M | (m) | $-2.89M | $-400.19M | $66.19M | $64.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $467.93M | (m) | $-2.47M | $-397.16M | $68.30M | $66.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $466.57M | (m) | $-2.77M | $-391.40M | $72.40M | $70.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $451.34M | $2.70M | $-3.07M | $-384.86M | $63.42M | $62.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $450.28M | (m) | $-2.08M | $-380.08M | $68.12M | $66.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $448.25M | (m) | $-2.61M | $-372.97M | $72.67M | $71.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $441.30M | (m) | $-3.11M | $-367.74M | $70.45M | $69.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $440.28M | $3.10M | $-3.57M | $-363.37M | $73.34M | $71.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $439.15M | (m) | $-3.18M | $-357.02M | $78.95M | $77.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $437.15M | (m) | $-3.36M | $-350.95M | $82.85M | $81.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $435.82M | (m) | $-5.09M | $-344.18M | $86.55M | $85.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $434.53M | (m) | $-5.21M | $-337.10M | $92.22M | $90.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $432.25M | (m) | $-3.43M | $-308.11M | $120.71M | $119.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $428.05M | (m) | $-3.05M | $-300.28M | $124.71M | $123.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $415.26M | (m) | $-2.09M | $-295.49M | $117.67M | $116.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $393.94M | (m) | $-3.67M | $-294.08M | $96.20M | $95.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $388.19M | (m) | $-821.00K | $-296.10M | $91.27M | $90.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $388.27M | (m) | $-486.00K | $-288.34M | $99.44M | $97.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $387.69M | (m) | $634.00K | $-281.82M | $106.50M | $104.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $387.06M | (m) | $-681.00K | $-273.42M | $112.96M | $111.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $386.45M | (m) | $-357.00K | $-268.94M | $117.16M | $115.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $385.62M | (m) | $207.00K | $-252.44M | $133.39M | $131.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $384.55M | (m) | $694.00K | $-222.40M | $161.24M | $161.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $354.27M | (m) | $1.43M | $-261.86M | $92.25M | $92.25M | (m) | (m) | (m) | (m) | 12 month · $4.91M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $386.86M | (m) | $1.17M | $-216.91M | $171.13M | $169.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $383.53M | (m) | $1.08M | $-283.63M | $100.98M | $104.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $379.19M | (m) | $198.00K | $-279.42M | $99.97M | $102.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $-328.00K | (m) |
| 2017-12-31 | $378.49M | (m) | $451.00K | $-216.30M | $162.64M | $164.26M | (m) | (m) | (m) | (m) | 12 month · $3.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $342.51M | (m) | $141.00K | $-144.36M | $198.29M | $208.99M | $0.00 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2017-06-30 | $334.54M | (m) | $271.00K | $-158.68M | $176.12M | $178.19M | $0.00 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2017-03-31 | $334.00M | (m) | $408.00K | $-147.03M | $187.37M | $189.70M | $0.00 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2016-12-31 | $317.88M | (m) | $-738.00K | $-196.32M | $117.93M | $130.51M | $0.00 | (m) | $2.89M | (m) | 12 month · $2.73M | (m) | (m) | (m) | (m) | 620.00K |
| 2016-09-30 | $313.51M | (m) | $-690.00K | $-190.53M | $119.39M | $136.24M | $0.00 | (m) | $2.89M | (m) | (m) | (m) | (m) | (m) | (m) | 620.00K |
| 2016-06-30 | $310.88M | (m) | $-504.00K | $-221.74M | $85.74M | $94.05M | $0.00 | (m) | $2.89M | (m) | (m) | (m) | (m) | (m) | (m) | 620.00K |
| 2016-03-31 | $275.24M | (m) | $-60.00K | $-246.29M | $10.85M | $59.59M | $0.00 | (m) | $18.03M | (m) | (m) | (m) | (m) | (m) | (m) | 4.47M |
| 2015-12-31 | $273.98M | (m) | $-237.00K | $-229.89M | $25.82M | $76.45M | $0.00 | (m) | $18.03M | (m) | 12 month · $2.00M | 12 month · $822.00K | (m) | (m) | (m) | 4.47M |
| 2015-09-30 | $248.07M | (m) | $-87.00K | $-215.76M | $13.04M | $60.93M | $0.00 | (m) | $19.18M | (m) | (m) | (m) | (m) | (m) | (m) | 4.72M |
| 2015-06-30 | $235.56M | (m) | $-131.00K | $-202.06M | $16.98M | $64.95M | $3.50M | (m) | $19.89M | (m) | (m) | (m) | (m) | (m) | (m) | 4.89M |
| 2015-03-31 | $234.75M | (m) | $238.82K | $-192.36M | $26.25M | $57.51M | $3.50M | $7.14K | $19.89M | (m) | (m) | (m) | (m) | (m) | (m) | 4.89M |
| 2014-12-31 | $234.85M | (m) | $186.00K | $-182.19M | $36.46M | $62.72M | $3.50M | $7.14K | $19.89M | (m) | 12 month · $2.41M | 12 month · $234.00K | (m) | (m) | (m) | 4.89M |
| 2014-09-30 | $201.30M | (m) | $-150.69K | $-171.61M | $10.98M | $38.95M | $3.50M | $59.93K | $22.12M | (m) | (m) | (m) | (m) | (m) | (m) | 5.40M |
| 2014-06-30 | $199.94M | (m) | $-85.13K | $-163.39M | $17.91M | $46.58M | $3.50M | $59.93K | $22.12M | (m) | (m) | (m) | (m) | (m) | (m) | 5.40M |
| 2014-03-31 | $211.94M | (m) | $-44.34K | $-153.88M | $19.24M | $45.36M | $3.50M | $93.97K | $42.37M | (m) | (m) | (m) | (m) | (m) | (m) | 10.55M |
| 2013-12-31 | $203.46M | (m) | $62.90K | $-145.78M | $14.80M | $42.26M | $0.00 | $93.97K | $43.03M | 12 month · $541.80K | 12 month · $2.14M | (m) | (m) | (m) | (m) | 10.70M |
| 2013-09-30 | $149.01M | (m) | $124.74K | $-126.17M | $12.94M | $25.37M | $0.00 | $93.97K | $10.12M | (m) | (m) | (m) | (m) | (m) | (m) | 2.32M |
| 2013-06-30 | $148.00M | (m) | $117.72K | $-117.18M | $20.92M | $34.52M | (m) | $93.97K | $10.12M | (m) | (m) | (m) | (m) | (m) | (m) | 2.32M |
| 2013-03-31 | $135.59M | (m) | $88.87K | $-109.61M | $15.84M | $29.98M | (m) | $93.97K | $10.32M | (m) | (m) | (m) | (m) | (m) | (m) | 2.36M |
| 2012-12-31 | $119.82M | (m) | $-59.57K | $-101.90M | $9.58M | $24.29M | $0.00 | $93.97K | $8.38M | (m) | 12 month · $1.56M | (m) | (m) | (m) | (m) | 1.80M |
| 2012-09-30 | $120.91M | (m) | $-197.38K | $-95.86M | $16.94M | $29.21M | (m) | $93.97K | $8.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.71M |
| 2012-06-30 | $120.16M | (m) | $-181.61K | $-90.90M | $23.18M | $34.29M | (m) | $93.97K | $6.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.29M |
| 2012-03-31 | $115.55M | (m) | $1.34K | $-85.43M | $24.20M | $35.83M | (m) | $93.97K | $6.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.29M |
| 2011-12-31 | $115.14M | (m) | $-122.75K | $-80.47M | $28.65M | $41.46M | $0.00 | $93.97K | $6.00M | (m) | 12 month · $1.51M | (m) | (m) | 12 month · $3.21M | (m) | 1.29M |
| 2011-09-30 | $114.74M | (m) | $-99.49K | $-75.11M | $33.62M | $46.92M | $0.00 | $93.97K | $-6.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.29M |
| 2011-06-30 | $108.35M | (m) | $-701.20K | $-71.60M | $36.14M | $48.87M | $0.00 | $93.97K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $101.14M | (m) | $897.34K | $-63.95M | $38.17M | $49.43M | $0.00 | $93.97K | $0.00 | (m) | 12 month · $1.03M | (m) | (m) | 12 month · $5.89M | (m) | 0.00 |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $11.05M | (m) | (m) | (m) | (m) | 12 month · $488.56K | (m) | 12 month · $304.40K | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-4.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |